Currently, some of the major pharma and biotech giants such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others are actively working in the Biliary Tract Cancers (BTCs) Market.
DelveInsight’s “Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Biliary Tract Cancers market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Biliary Tract Cancers market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Biliary Tract Cancers: An Overview
Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumor), and distal CCA. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the gallbladder tissues. It originates in the gallbladder cells, and most are adenocarcinoma, which begins in the gland cells of the gallbladder lining. Cholangiocarcinoma is a type of cancer that develops within the bile duct system, a series of small tubes that transport bile fluid from the liver (where it is produced) to the gallbladder (where it is produced it is stored).
The common malignant hepatic lesions include hepatocellular carcinoma (HCC), Biliary Tract Cancer (BTC), and other metastatic diseases. Biliary tract cancer (BTC) constitutes epithelial malignancies of the biliary tree and includes the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumor), and distal CCA.
In upcoming years, advancement in diagnosis and proper understanding of the role of genetic aberrations, particularly in regions encoding key components of signaling pathways, allow researchers to approach Biliary Tract Cancer in new directions and make discoveries.
Biliary Tract Cancers Market Key Facts
-
The total market size of Biliary Tract Cancer in the United States was found to be USD 237 million in 2021.
-
In EU5, the total market size of Biliary Tract Cancer was USD 163 million in 2021.
-
In Japan, the total market size of Biliary Tract Cancer was USD 153 million in 2021.
-
In the year 2021, the total incident cases of BTC were found to be 37,400+ in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Biliary Tract Cancers market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Biliary Tract Cancers market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Biliary Tract Cancers Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Biliary Tract Cancers (BTCs) Epidemiology Segmented as –
-
Total incident cases of BTC in the 7MM [2019–2032]
-
Total age-specific cases of BTC in the 7MM [2019–2032]
-
Total mutation-specific Cases of BTC in the 7MM [2019–2032]
-
Total stage-specific cases of BTC in the 7MM [2019–2032]
-
Total treated Cases of BTC in the 7MM [2019–2032]
Biliary Tract Cancers Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Biliary Tract Cancers market or expected to be launched during the study period. The analysis covers the Biliary Tract Cancers market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Tract Cancers pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Biliary Tract Cancers Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Biliary Tract Cancers Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Asthma. Currently, AstraZeneca is leading the therapeutics market with its biliary tract cancer drug candidates in the most advanced stage of clinical development.
Leading Companies in the Biliary Tract Cancers (BTCs) Therapeutics Market Include:
Adherex Technologies, Inc., Agios Pharmaceuticals, AstraZeneca, Basilea Pharmaceutica, Bayer, BeiGene, BioNTech SE, Black Diamond Therapeutics, Inc., Chia Tai Tianqing Pharmaceutical Group, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Delcath Systems, DualityBio Inc., Eisai, Eli Lilly and Company, Genentech, H. Lee Moffitt Cancer Center and Research Institute, Handok Inc., Hoffmann-La Roch, Incyte Corporation, InnoPharmax Inc., Jiangsu HengRui Medicine Co., Ltd., Leap Therapeutics, Inc., Lee’s Pharmaceutical Limited, Loxo Oncology, Medicenna Therapeutics, Inc., Merck Sharp & Dohme Corp., Miracogen, National Cancer Institute (NCI), QED Therapeutics, RaND Biosciences, RemeGen Co., Ltd., Roche, Servier Pharmaceuticals, Shanghai Miracogen Inc., Silverback Therapeutics, Sorrento Therapeutics, Inc., Taiho Oncology, Inc., TransThera Sciences (Nanjing), Zai Lab (Shanghai) Co., Ltd., Zymeworks Inc., and many others.
Biliary Tract Cancers (BTCs) Emerging and Marketed Drugs Covered in the Report Include:
-
ARQ 087 (Derazantinib): Basilea Pharmaceutica
-
AZD5305: Astra Zeneca
-
E7090 (tasurgratinib): Eisai
-
Futibatinib (TAS-120): Taiho Oncology
-
Imfinzi (durvalumab): AstraZeneca
-
Keytruda (pembrolizumab): Merck Sharp & Dohme
-
Lenvima (lenvatinib): Eisai and Merck & Co
-
Melphalan: Delcath Systems
-
MRG 002: Miracogen
-
Ramucirumab: Eli Lilly and Company
-
TT-00420: TransThera Sciences (Nanjing)
-
Zanidatamab: Zymeworks and BeiGene
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Biliary Tract Cancers Competitive Intelligence Analysis
4. Biliary Tract Cancers Market Overview at a Glance
5. Biliary Tract Cancers Disease Background and Overview
6. Biliary Tract Cancers Patient Journey
7. Biliary Tract Cancers Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Biliary Tract Cancers Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Tract Cancers Unmet Needs
10. Key Endpoints of Biliary Tract Cancers Treatment
11. Biliary Tract Cancers Marketed Products
12. Biliary Tract Cancers Emerging Drugs and Latest Therapeutic Advances
13. Biliary Tract Cancers Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Tract Cancers Market Outlook (In US, EU5, and Japan)
16. Biliary Tract Cancers Access and Reimbursement Overview
17. KOL Views on the Biliary Tract Cancers Market
18. Biliary Tract Cancers Market Drivers
19. Biliary Tract Cancers Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/